MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$2.90 USD
-0.03 (-1.02%)
Updated Jun 14, 2024 02:29 PM ET
4-Sell of 5 4
A Value B Growth D Momentum A VGM
Brokerage Reports
0 items in cart
MEI Pharma, Inc. [MEIP]
Reports for Purchase
Showing records 1 - 20 ( 141 total )
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MEIP 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Voruciclib and ME-344 Look to Drive a New Narrative for MEI; Reit. Buy and Lowering our PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Zandelisib Data Expected at ASH ?22, As Other Clinical Assets Move Forward; Reit. Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Zandelisib Continues to Move Forward on a Longer Path Towards Approval; Reit. Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Considerations on the Future of Zandelisib Following FDA AdCom; Reit Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Zandelisib Story Requires Extra Patience, But Not All Hope is Lost; Reit. Buy and Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Zandelisib NDA Remains Central Focus; Reit. Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Positive TIDAL Data Further Differentiates Zandelisib Among PI3Ka Inhibitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Awaiting TIDAL to Make a Positive Splash in FL; Reit Buy and PT $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Top-Line TIDAL Data Remains Central Focus; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Zandelisib Showcases Efficacy Across FL and Other B-cell Malignancies During ASCO ?21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
TIDAL and COASTAL Programs Set to Advance Zandelisib in 2021; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Preclinical Data For Vorociclib Presented At AACR 2021 Highlights Its Potential In KRAS-mutant Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
PI3K Inhibitor Takes the Podium; Ukoniq Readthrough to Zandelisib
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
A Tidal Wave of Milestones Expected in 2021; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Kicking off 2021 with Positive Clinical Program Updates; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
Primary Focus on Zandelisib Development Programs; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MEI Pharma, Inc.
Industry: Medical - Drugs
MEIP Finishing FY20 Strong With Notable Catalysts Going Into FY21; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A